Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Multi-site Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.

NCT03902509 is registered in ClinicalTrials.gov with Beijing Continent Pharmaceutical Co, Ltd. as lead sponsor.

NCT NCT03902509
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03902509 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Multi-site Study About Safety and Efficacy of Pirfenidone to Treat Grade 2 or Grade3 Radiation-induced Lung Injury.
Lead sponsor
Beijing Continent Pharmaceutical Co, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
May 24, 2019
Completion date
December 4, 2023
Enrollment
126 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

radiation-induced lung injury